Medix Biochemica expands its infectious diseases antibody offering through the acquisition of ViroStatNovember 10, 2023
- Medix Biochemica has acquired 100 percent of the shares of US-based ViroStat LLC, a global leader in infectious disease antibodies and antigens used by in vitro diagnostics (“IVD”) manufacturers.
- The acquisition significantly expands Medix Biochemica’s leading portfolio of IVD raw materials, brings complementary scientific capabilities and further strengthens its local presence in the USA.
- The transaction accelerates Medix Biochemica’s strategic vision of becoming the first-choice partner for the IVD industry worldwide and positions the organization as a market leader in the supply of critical raw materials to combat infectious diseases.
Medix Biochemica, a global leader in the supply of critical raw materials to the in vitro diagnostics industry, has acquired 100 percent of the shares of ViroStat. As a result of the partnership, Medix Biochemica will be able to provide its customers with market-leading infectious disease antibodies and antigens for their IVD immunoassay test development. ViroStat operations will remain in Westbrook, Maine, and its employees – including President Dr. Douglas McAllister and General Manager Duncan McAllister – will join Medix Biochemica following the acquisition.
Founded in 1985 by Dr. Douglas McAllister, ViroStat is a globally leading primary manufacturer of high-quality antibodies and antigens used for the detection of respiratory agents, STD agents, gastrointestinal agents/toxins and food borne pathogens. For example, the company is widely known for its high affinity antibodies to Influenza A, Influenza B, RSV and Strep A for use in rapid lateral flow devices. ViroStat is headquartered and has its production site in Westbrook, Maine.
“We are very excited to welcome the whole ViroStat team to Medix Biochemica,” says Steve Ferguson, CEO of Medix Biochemica. “The partnership with ViroStat provides Medix Biochemica with market-leading products for broad range of infectious diseases as well as further strengthens our scientific capabilities and network in this largest diagnostic area of IVD antibodies and antigens. There has been a long-standing business relationship between ViroStat and Medix Biochemica, and we have great respect for what Doug, Duncan and the whole ViroStat team have built over the last 38 years. I am highly excited about the portfolio and cultural fit between our teams and looking forward to jointly growing our business to enable our customers to combat infectious diseases globally”.
Douglas McAllister, President of ViroStat notes that “partnering with Medix Biochemica represents an exciting synergy of complementary product portfolios. ViroStat brings validated antibody pairs especially for rapid test IVDs at a time when worldwide demand for self-testing is poised for rapid growth while our R&D activity endeavors to stay ahead of new and emerging pathogens. We are very pleased and excited to be joining the Medix Biochemica family. This is a great fit.”
For more information, visit www.medixbiochemica.com
About Medix Biochemica
With Finnish roots and rapidly growing global branches, Medix Biochemica is a market-leading, independent supplier of critical raw materials to the in vitro diagnostics (IVD) industry worldwide. We develop, produce, and supply high-quality antibodies, antigens, and other critical IVD raw material products to our IVD partners all around the world, enabling the delivery of accurate IVD tests to billions of patients worldwide. Our expertise covers everything from immuno- and molecular diagnostic reagents to biospecimen and custom services. With the most comprehensive raw material portfolio in the IVD world, and a team made up of the best minds in the business, we help shorten our customers’ time to market and build quality into every one of their tests. Medix Biochemica employs 270 professionals worldwide and we serve our global customers through our local teams in North America, Europe, and China. The company's main owner is DevCo Partners, a long-term oriented active owner and development partner dedicated to building world-leading companies in selected niche markets.
ViroStat LLC is a primary manufacturer of infectious disease antibodies and antigens, supplying manufacturers and researchers since 1985. The US-based company is recognized for high-quality antibodies with batch consistency and supply reliability, combined with excellent customer service, technical support, and long-term relationships.
Corporate, Finance & Investor,